Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both
World Journal of Hepatology,
Год журнала:
2024,
Номер
16(6), С. 871 - 877
Опубликована: Июнь 19, 2024
Sarcopenia
and
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD)
are
closely
intertwined.
Sarcopenia,
traditionally
a
of
the
older
adult
chronic
population,
has
been
studied
as
one
pathophysiologic
conditions
at
play
in
development
MASLD.
They
share
similar
risk
factors
insulin
resistance
physical
inactivity.
Given
pathophysiology
along
liver-muscle
axis,
sarcopenia
factor
for
MASLD,
vice
versa.
Current
research
suggests
bidirectional
relationship.
chronicity
MASLD
inflammatory
disease,
it
can
break
down
muscle
mass
lead
to
sarcopenia,
while
promotes
intramuscular
lipid
accumulation
that
releases
cytokines
aggravate
inflammation
liver.
However,
longest
time,
lack
consensus
definition
made
difficult
study
their
relationship
outcomes.
A
recent
nomenclature
update
diagnosing
easier
researchers
identify
cohorts
study.
no
gold
standard
technique
measure
or
identified
yet.
Future
studies
needed
reach
reduce
diagnostic
variation.
With
shared
between
two
diseases,
future
may
also
potential
therapeutic
targets
axis
would
benefit
both
order
maximize
Язык: Английский
In vitro antioxidant effects and in vivo hepatoprotective effects of Osbeckia octandra, Vernonia cinerea and Atalantia ceylanica on a high fat diet induced metabolic dysfunction-associated steatotic liver disease mouse model
BMC Complementary Medicine and Therapies,
Год журнала:
2025,
Номер
25(1)
Опубликована: Май 23, 2025
Язык: Английский
Effect of L-carnitine supplementation on muscle cramps in liver cirrhosis: results from a retrospective cohort study
BMC Gastroenterology,
Год журнала:
2025,
Номер
25(1)
Опубликована: Март 9, 2025
Muscle
cramps
are
among
the
common
debilitating
complications
of
liver
cirrhosis.
Since
this
complication
lacks
effective
treatments,
we
aimed
to
evaluate
effectiveness
L-carnitine
supplementation
in
reducing
frequency,
duration,
and
severity
muscle
patients
with
The
present
retrospective
cohort
was
conducted
on
adult
referred
between
November
2022
December
2023
a
tertiary
referral
hospital
Shiraz,
Iran.
Patients
confirmed
cirrhosis
who
had
≥
4
times
per
month
without
other
secondary
etiologies
for
were
evaluated
inclusion.
They
included
if
they
taken
an
oral
supplement
1000
mg/day
one
available
medical
records
assessment
their
before
after
starting
supplement.
From
702
screened,
195
(27.8%)
cramps,
91
(13.0%)
met
inclusion
criteria.
respective
median
age
duration
(interquartile
range
(IQR))
61.0
(16.0)
2.0
(3.0)
years,
48
(53%)
male.
Median
daily,
weekly,
monthly
cramp
frequency
higher
females
(P-values
<
0.05).
We
noted
reduced
severity,
mean
following
(respective
(IQR)
absolute
percentage
change:
100
(100.0),
60
(88.33),
50
(75.0),
(77.5),
40.0
(44.58);
P-values
0.001).
Additionally,
completely
resolved
29
(31.9%),
21
(23.1%),
13
(14.3%)
supplementation.
BMI
correlated
change
all
mentioned
indices
0.05),
(P-value
=
0.042).
Changes
did
not
differ
significantly
males
females.
seems
be
promising
therapeutic
option
Further
studies
control
groups
larger
samples
required
confirm
finding.
Язык: Английский
Lean-MAFLD: imperatives for updated evidence, mechanistic clarity, and methodological rigor
Hepatology International,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 22, 2025
Язык: Английский
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(10), С. 4673 - 4673
Опубликована: Май 14, 2025
Metabolic-Associated
Fatty
Liver
Disease
(MAFLD)
is
a
public
health
concern
that
constantly
expanding,
with
fast-growing
prevalence,
and
it
affects
about
quarter
of
the
world's
population.
This
condition
significant
risk
factor
for
cardiovascular,
hepatic,
oncologic
diseases,
such
as
hypertension,
hepatoma,
atherosclerosis.
Sarcopenia
was
long
considered
to
be
an
aging-related
syndrome,
but
today,
acknowledged
secondarily
related
chronic
diseases
metabolic
cardiovascular
conditions,
liver
among
other
comorbidities
associated
insulin
resistance
inflammation,
besides
inactivity
poor
nutrition.
The
physiopathology
involving
MAFLD
sarcopenia
has
still
not
been
solved.
Inflammation,
oxidative
stress,
mitochondrial
dysfunction,
seem
some
keys
this
relationship
since
hormone
target
mainly
skeletal
muscle.
review
aimed
comprehensively
discuss
main
physiological
pathways
involved
in
these
conditions.
are
interconnected
by
complex
network
pathophysiological
mechanisms,
resistance,
muscle
tissue
production
capacity,
inflammatory
state,
which
contributors
relationship.
In
addition,
clinical
analysis,
patients
manifest
more
severe
hepatitis
fibrosis
when
compared
only
MAFLD.
These
patients,
both
disorders,
also
present
improvement
their
treated
sarcopenia,
reinforcing
association
between
them.
Lifestyle
changes
accompanied
non-pharmacological
interventions,
dietary
therapy
increased
physical
activity,
undoubtedly
improve
scenario.
Язык: Английский
Riesgo de enfermedad del hígado graso asociada a la disfunción metabólica en 44.939 trabajadores sanitarios españoles: variables asociadas
Medicina de Familia SEMERGEN,
Год журнала:
2025,
Номер
51(7), С. 102514 - 102514
Опубликована: Май 30, 2025
Язык: Английский
Triglyceride-Targeted Molecularly Imprinted Polymers Activate Lipophagy via Cargo Exchange for Nonalcoholic Fatty Liver Disease Treatment
ACS Applied Polymer Materials,
Год журнала:
2024,
Номер
6(12), С. 7265 - 7277
Опубликована: Июнь 14, 2024
Lipid
accumulation
is
a
prominent
pathologic
feature
of
nonalcoholic
fatty
liver
disease
(NAFLD),
which
due
to
imbalances
in
triglycerides
metabolism.
However,
none
the
available
therapeutic
strategies
have
been
able
achieve
effective
removal
from
lesion
site.
Herein,
MIP@QUE,
mimetic
transporter
with
high
affinity
for
triglycerides,
was
synthesized
using
molecular
imprinting.
The
physicochemical
features
MIP@QUE
are
such
that
it
binds
and
releases
drug
an
affinity-driven
reaction.
In
vivo
vitro
experiments
showed
metabolism
promoted
by
dual
activation
autophagy-lysosomal
pathway
through
size
effect
molecularly
imprinted
polymer
(MIP)
pharmacological
action
quercetin
(QUE).
Moreover,
not
only
reduced
triglyceride
reverse
hepatic
steatosis
but
also
effectively
lowered
level
oxidative
stress
reduce
hepatocellular
damage.
Targeting
key
causative
factors
NAFLD,
offers
strategy
control
process
promoting
lysosomal
transport
hepatocytes;
serves
as
platform
treatment
triglyceride-related
metabolic
syndrome.
Язык: Английский